HCPCS Level II E0765: Nerve Stimulator for Treatment of Nausea and Vomiting
HCPCS Level II code E0765 identifies an FDA-approved nerve stimulator used for the treatment of nausea and vomiting. This code captures the provision of a neuromodulation device intended to manage refractory or treatment-resistant nausea/vomiting, an area of growing clinical interest as nonpharmacologic interventions expand. Nationally, device-based therapies can affect utilization patterns in gastroenterology, otolaryngology, and pain management settings and have implications for durable medical equipment and outpatient procedure billing.
Key payers covered in typical analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical purpose of the device, typical sites of service where the device is supplied or managed, and the billing context for a device-based neuromodulation therapy. The publication also outlines common billing modifiers and payer considerations where available, and summarizes what to expect in payer coverage and coding workflows. Data not available in the input will be noted as such in relevant sections.
Customize your policy alerts
Sign up for hcpcs E0765 policy alerts
Get alerted when payer policies referencing E0765 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code E0765 describes an FDA-approved nerve stimulator for treatment of nausea and vomiting. The service represented is the provision of a medical device-based neuromodulation therapy intended to reduce or control symptoms of nausea and vomiting when clinically indicated. Typical site of service is ambulatory clinic or outpatient specialty clinic, and may also include hospital outpatient departments where device evaluation, fitting, or monitoring are performed.